New Pain Therapeutics Summit 2007 Announced
Arrowhead Conferences, a wing of Arrowhead Publishers, has announced their upcoming Pain Therapeutics Summit 2007, to take place in Jersey City, New Jersey on October 25th and 26th, 2007.
About one and a half billion people suffer from moderate to severe chronic pain worldwide and approximately 50 million Americans suffer with pain. The value of the pharmaceutical market for pain relief reflects this seeming worldwide epidemic of pain, with the overall value estimated at over $25 billion. There is thus great unmet need in the pharmacological treatment of pain around the world.
Arrowhead Conferences' Pain Therapeutics Summit 2007 brings together leaders from the pharmaceutical community to discuss new avenues of research in the field of pain therapeutics and the latest advances in the field.
At this conference, hear from experts in the field regarding new targets for pain relief in the areas of neuropathic pain, nociceptive pain, migraine pain, cancer pain, chronic pain and inflammatory conditions. Moreover, special consideration will be given to the roles that drug delivery and devices will play in the future management of pain.
Key themes of this conference will include: New drug discovery and targets in the area of pain management, Focus on clinical trials and regulatory issues facing developers of new pain medications, Specialty Pharma drug development activities in pain management, Licensing and investment issues revolving around the pain therapeutics market, Developments in the race to market abuse-resistant opioids, and Drug delivery technologies and their application to the field of pain management.
Therapeutic areas covered at this conference will include: neuropathic pain, migraine relief, chronic pain, nociceptive pain (eg. osteoarthritis, cancer pain).
Drug classes covered in this conference will include cannabinoids, triptans, anticonvulsants, opioids and analgesics.
For more information, visit arrowheadpublishers.com
About one and a half billion people suffer from moderate to severe chronic pain worldwide and approximately 50 million Americans suffer with pain. The value of the pharmaceutical market for pain relief reflects this seeming worldwide epidemic of pain, with the overall value estimated at over $25 billion. There is thus great unmet need in the pharmacological treatment of pain around the world.
Arrowhead Conferences' Pain Therapeutics Summit 2007 brings together leaders from the pharmaceutical community to discuss new avenues of research in the field of pain therapeutics and the latest advances in the field.
At this conference, hear from experts in the field regarding new targets for pain relief in the areas of neuropathic pain, nociceptive pain, migraine pain, cancer pain, chronic pain and inflammatory conditions. Moreover, special consideration will be given to the roles that drug delivery and devices will play in the future management of pain.
Key themes of this conference will include: New drug discovery and targets in the area of pain management, Focus on clinical trials and regulatory issues facing developers of new pain medications, Specialty Pharma drug development activities in pain management, Licensing and investment issues revolving around the pain therapeutics market, Developments in the race to market abuse-resistant opioids, and Drug delivery technologies and their application to the field of pain management.
Therapeutic areas covered at this conference will include: neuropathic pain, migraine relief, chronic pain, nociceptive pain (eg. osteoarthritis, cancer pain).
Drug classes covered in this conference will include cannabinoids, triptans, anticonvulsants, opioids and analgesics.
For more information, visit arrowheadpublishers.com
Labels: migraine pain
posted by Ron King at 2:23 PM
<< Home